VIP
Vasoactive intestinal peptide
A 28-amino-acid peptide of the secretin/glucagon superfamily, first isolated from porcine intestine and since found throughout the nervous system. It binds two G-protein-coupled receptors, VPAC1 and VPAC2, and shares a receptor family with the GLP-1 analogues in this directory despite an entirely separate physiological role.
Vasoactive intestinal peptide has 9 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 1,031 planned or enrolled participants across the 7 studies that published a figure. No FDA-approved product contains Vasoactive intestinal peptide. 1,368 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Vasoactive intestinal peptide; the registry search is fuzzy, so every match is re-checked. None of this says whether Vasoactive intestinal peptide works or is safe.
FDA status
Research only
Human studies
9
Furthest phase
Phase 3
Papers, 10 yr
1,368
Readership
2,112
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
9
Registered human studies
Phase 3
Furthest phase reached
1,031
Planned or enrolled participants, across 7 studies that published a figure
None
No FDA-approved product contains it
19 loose registry matches were checked and 9 confirmed — 10 named something else and were discarded. We count a study only when Vasoactive intestinal peptide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Vasoactive intestinal peptide is, and what it has been studied for
Vasoactive intestinal peptide is classified by ChEMBL as a protein. Its FDA substance identifier is 6J2WVD66KR.
Across 9 registered trials, it has been studied in Migraine, Covid19, Sepsis and Respiratory Distress Syndrome. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Danish Headache Center and National Institute of Allergy and Infectious Diseases (NIAID) among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Vasoactive intestinal peptide reached Phase 3 across 9 registered trials.
No FDA-approved product contains Vasoactive intestinal peptide. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Vasoactive intestinal peptide?
Papers published each year that name Vasoactive intestinal peptide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 120 | 0 | Yes |
| 2018 | 157 | 0 | Yes |
| 2019 | 177 | 1 | Yes |
| 2020 | 153 | 1 | Yes |
| 2021 | 160 | 2 | Yes |
| 2022 | 161 | 0 | Yes |
| 2023 | 172 | 0 | Yes |
| 2024 | 157 | 0 | Yes |
| 2025 | 184 | 0 | Yes |
| 2026 | 109 | 0 | No |
1,368 papers and 4 registered trials between 2017 and 2026. A paper counts when “Vasoactive intestinal peptide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Vasoactive intestinal peptide
1,368 indexed papers name Vasoactive intestinal peptide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Vasoactive intestinal peptide secreting tumour: An overview
- Vasoactive Intestinal Peptide-Secreting Tumors: A Review
- Vasoactive intestinal peptide
- The role of vasoactive intestinal peptide in pulmonary diseases
- A Role for Vasoactive Intestinal Peptide Interneurons in Neurodevelopmental Disorders
- Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
- Role of vasoactive intestinal peptide in osteoarthritis
- Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system
Collected 2026-08-02from PubMed, phrase-matched on “Vasoactive intestinal peptide” in title and abstract. Run the same search.
About Vasoactive intestinal peptide
A 28-amino-acid peptide of the secretin/glucagon superfamily, first isolated from porcine intestine and since found throughout the nervous system. It binds two G-protein-coupled receptors, VPAC1 and VPAC2, and shares a receptor family with the GLP-1 analogues in this directory despite an entirely separate physiological role.
- Also known as
- VIP · Aviptadil
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.